Viral Vectors in Gene Therapy and Clinical Aplications

Mahoney, A; Nassif, N; O'Brien, B; Simpson, A

Viral Vectors in Gene Therapy and Clinical Aplications

Mahoney, A Nassif, N

O'Brien, B Simpson, A

Permalink

Publisher:: IntechOpen
Publication Type:: Chapter
Citation:: Molecular Cloning, 2022, 1
Issue Date:: 2022-07

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (897.6 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Mahoney, A
dc.contributor.author	Nassif, N https://orcid.org/0000-0003-2675-8322
dc.contributor.author	O'Brien, B
dc.contributor.author	Simpson, A https://orcid.org/0000-0002-2249-5097
dc.contributor.editor	Dincer, S
dc.date.accessioned	2023-03-10T06:23:24Z
dc.date.available	2023-03-10T06:23:24Z
dc.date.issued	2022-07
dc.identifier.citation	Molecular Cloning, 2022, 1
dc.identifier.isbn	1803554509
dc.identifier.isbn	9781803554501
dc.identifier.uri	http://hdl.handle.net/10453/166973
dc.description.abstract	Developments in gene therapy, coupled with advances in genome sequencing and a greater understanding of DNA sequences, have given rise to an exciting area of research. The use of viral vectors in gene therapy has become a very promising and fast-emerging technology over the past few decades. Despite previous setbacks, the approval of viral vector therapies worldwide, with many in late-stage clinical trials has led to a significant increase in research in this area of gene therapy. Retroviral, adenoviral, adeno-associated viral, and lentiviral vectors are all key vectors currently being researched and used in clinical trials. There are many challenges with the use of viral vectors that are yet to be overcome including cost of production, the immune response, and the ability to precisely regulate the expression of the transgene. However, with increased numbers of clinical trials showing efficacy, safety, and growing financial investment, the future use of viral vectors in gene therapy is increasingly promising.
dc.format	Print and online
dc.format.extent	5
dc.language	en
dc.publisher	IntechOpen
dc.relation.ispartof	Molecular Cloning
dc.relation.isbasedon	10.5772/intechopen.102559
dc.rights	info:eu-repo/semantics/openAccess
dc.title	Viral Vectors in Gene Therapy and Clinical Aplications
dc.type	Chapter
utslib.citation.edition	1
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	/University of Technology Sydney/Centre for Health Technologies (CHT)
utslib.copyright.status	open_access	*
pubs.consider-herdc	true
dc.date.updated	2023-03-10T06:23:23Z
pubs.edition	1
pubs.publication-status	Published

Abstract:

Developments in gene therapy, coupled with advances in genome sequencing and a greater understanding of DNA sequences, have given rise to an exciting area of research. The use of viral vectors in gene therapy has become a very promising and fast-emerging technology over the past few decades. Despite previous setbacks, the approval of viral vector therapies worldwide, with many in late-stage clinical trials has led to a significant increase in research in this area of gene therapy. Retroviral, adenoviral, adeno-associated viral, and lentiviral vectors are all key vectors currently being researched and used in clinical trials. There are many challenges with the use of viral vectors that are yet to be overcome including cost of production, the immune response, and the ability to precisely regulate the expression of the transgene. However, with increased numbers of clinical trials showing efficacy, safety, and growing financial investment, the future use of viral vectors in gene therapy is increasingly promising.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/166973